KRAS-G12D mutation drives immune suppression and the primary resistance of anti-PD-1/PD-L1 immunotherapy in non-small cell lung cancer.
Liu C, Zheng S, Wang Z, Wang S, Wang X, Yang L, Xu H, Cao Z, Feng X, Xue Q, Wang Y, Sun N, He J.
Liu C, et al. Among authors: wang x, wang z, wang y, wang s.
Cancer Commun (Lond). 2022 Sep;42(9):828-847. doi: 10.1002/cac2.12327. Epub 2022 Jul 11.
Cancer Commun (Lond). 2022.
PMID: 35811500
Free PMC article.